US Patent Issued to Arrowhead Pharmaceuticals on May 19 for "RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use" (Wisconsin Inventors)

ALEXANDRIA, Va., May 19 -- United States Patent no. 12,630,826, issued on May 19, was assigned to Arrowhead Pharmaceuticals Inc. (Pasadena, Calif.).

"RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use" was invented by Anthony Nicholas (Oregon, Wis.), Tao Pei (Middleton, Wis.), Zhao Xu (Brookfield, Wis.), Daniel Braas (Madison, Wis.) and Zhi-Ming Ding (Waunakee, Wis.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit xanthine dehydrogenase (XDH) gene expression. Also disclosed are pharmaceutical compositions that include XDH RNAi agents and m...